Renaissance Technologies
SYRE icon

Renaissance Technologies’s Spyre Therapeutics SYRE Stock Holding History

Renaissance Technologies’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-30,936
Closed -$463K – 3909
2025
Q2 		$463K Buy
+30,936
New +$458K ﹤0.01% 2873
2024
Q2 		– Sell
-49,468
Closed -$1.88M – 3949
2024
Q1 		$1.88M Buy
49,468
+932
+2% +$27K ﹤0.01% 2074
2023
Q4 		$1.04M Buy
48,536
+25,307
+109% +$349K ﹤0.01% 2378
2023
Q3 		$285K Buy
23,229
+7,509
+48% +$99.3K ﹤0.01% 2949
2023
Q2 		$177K Buy
15,720
+8,476
+117% +$40.2K ﹤0.01% 3330
2023
Q1 		$53K Buy
7,244
+1,200
+20% +$13.2K ﹤0.01% 3652
2022
Q4 		$68K Sell
6,044
-3,948
-40% -$71K ﹤0.01% 3729
2022
Q3 		$131K Sell
9,992
-13,306
-57% -$164K ﹤0.01% 3506
2022
Q2 		$294K Buy
23,298
+17,223
+284% +$604K ﹤0.01% 3465
2022
Q1 		$349K Sell
6,075
-3,853
-39% -$324K ﹤0.01% 3399
2021
Q4 		$1.18M Buy
9,928
+5,916
+147% +$934K ﹤0.01% 2525
2021
Q3 		$797K Buy
4,012
+1,981
+98% +$346K ﹤0.01% 2670
2021
Q2 		$353K Buy
2,031
+1,611
+384% +$293K ﹤0.01% 3090
2021
Q1 		$83K Sell
420
-1,548
-79% -$297K ﹤0.01% 3231
2020
Q4 		$387K Sell
1,968
-11,922
-86% -$2.47M ﹤0.01% 2935
2020
Q3 		$2.46M Sell
13,890
-8,272
-37% -$1.53M ﹤0.01% 2004
2020
Q2 		$5.13M Sell
22,162
-1,824
-8% -$347K ﹤0.01% 1634
2020
Q1 		$2.79M Buy
23,986
+950
+4% +$162K ﹤0.01% 1883
2019
Q4 		$4.4M Buy
23,036
+608
+3% +$119K ﹤0.01% 1930
2019
Q3 		$4.31M Buy
22,428
+628
+3% +$122K ﹤0.01% 1877
2019
Q2 		$3.73M Buy
21,800
+3,648
+20% +$631K ﹤0.01% 1985
2019
Q1 		$3.65M Sell
18,152
-108
-0.6% -$22.5K ﹤0.01% 2004
2018
Q4 		$3.42M Sell
18,260
-430
-2% -$91.2K ﹤0.01% 1964
2018
Q3 		$4.47M Sell
18,690
-2,438
-12% -$569K ﹤0.01% 1881
2018
Q2 		$5.59M Buy
21,128
+17,048
+418% +$4.2M 0.01% 1716
2018
Q1 		$1.01M Buy
4,080
+2,796
+218% +$505K ﹤0.01% 2659
2017
Q4 		$174K Buy
1,284
+772
+151% +$94.4K ﹤0.01% 3160
2017
Q3 		$63K Sell
512
-496
-49% -$46.5K ﹤0.01% 3118
2017
Q2 		$97K Sell
1,008
-440
-30% -$60.8K ﹤0.01% 3087
2017
Q1 		$270K Buy
+1,448
New +$204K ﹤0.01% 2934

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Renaissance Technologies's SYRE Position: Q3 2025 in Review

Renaissance Technologies sold out of Spyre Therapeutics (SYRE) in Q3 2025, closing a stake of 30,936 shares — an estimated $463K sold.

Renaissance Technologies first reported a position in SYRE in Q1 2017 and held it in 30 quarters. The position peaked at $5.59M in Q2 2018. 137 funds tracked by Wall St. Rank hold SYRE as of Q3 2025.

  • Renaissance Technologies reported no remaining Spyre Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Renaissance Technologies sold 30,936 Spyre Therapeutics shares in Q3 2025, an estimated $463K.
  • Renaissance Technologies first reported a position in Spyre Therapeutics in Q1 2017 and held it in 30 quarters.
  • Renaissance Technologies's Spyre Therapeutics position peaked at $5.59M in Q2 2018.
  • 137 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q3 2025.

Based on Renaissance Technologies's 13F filing for Q3 2025, filed 13 Nov 2025.